KYNB insider transactions
Kyntra Bio Inc. (KYNB) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
KYNB insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Kyntra Bio Inc., latest first. Follow anyone to get their next filing.
- Thane WettigCEO, Director, since June 2020+$235K-$395K
- David DeLuciaChief Financial Officer, since December 2024
- Maykin HoDirector-$149K
- Jeffrey L EdwardsDirector-$136K
- Michael KauffmanDirector, since June 2025
- James A SchoeneckDirector+$225K-$128K
- Christine ChungSVP, China Operations-$789K
- Juan GrahamChief Financial Officer, since September 2021-$337K
- Deyaa AdibChief Medical Officer, since April 2024+$25.9K
- Aoife BrennanDirector-$81.4K
- Suzanne BlaugDirector-$147K
- Benjamin CravattDirector-$67.7K
- Gerald LemaDirector
- Mark EisnerOfficer-$588K
- Jeffrey William HendersonDirector-$133K
- Enrique A ConternoOfficer, Director-$1.82M
- Thomas F Kearns JrDirector-$782K
- Pat CotroneoOfficer-$104K
- Elias KouchakjiOfficer
- Kalevi KurkijarviDirector-$575K
Recent Form 3, 4, and 5 filings for KYNB
- SEC Form 4 filed by Kyntra Bio Inc.4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SEC Form 3 filed by Kyntra Bio Inc.3 - KYNTRA BIO, INC. (0000921299) (Issuer)
- CEO Wettig Thane covered exercise/tax liability with 209 shares, decreasing direct ownership by 0.77% to 26,796 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- Chief Financial Officer Delucia David covered exercise/tax liability with 22 shares, decreasing direct ownership by 0.50% to 4,355 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SEC Form 4 filed by Director Ho Maykin4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SEC Form 4 filed by Director Edwards Jeffrey L4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SEC Form 4 filed by Director Kauffman Michael4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SEC Form 4 filed by Director Schoeneck James A4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- CEO Wettig Thane covered exercise/tax liability with 198 shares, decreasing direct ownership by 0.73% to 27,005 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- Chief Financial Officer Delucia David covered exercise/tax liability with 52 shares, decreasing direct ownership by 1% to 4,377 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- Amendment: CEO Wettig Thane bought $19,852 worth of shares (2,800 units at $7.09), increasing direct ownership by 11% to 27,203 units (SEC Form 4)4/A - KYNTRA BIO, INC. (0000921299) (Issuer)
- CEO Wettig Thane decreased direct ownership by 9% to 27,203 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SEC Form 4 filed by Kyntra Bio Inc.4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SEC Form 4 filed by Kyntra Bio Inc.4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SEC Form 4 filed by CEO Wettig Thane4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Delucia David4 - KYNTRA BIO, INC. (0000921299) (Issuer)